<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-068417
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20091130
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20091204
<DATE-OF-FILING-DATE-CHANGE>20091204
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NEOGENOMICS INC
<CIK>0001077183
<ASSIGNED-SIC>8734
<IRS-NUMBER>742897368
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>333-72097
<FILM-NUMBER>091223311
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1726 MEDICAL BOULEVARD, SUITE 201
<STREET2>SUITE 201
<CITY>NAPLES
<STATE>FL
<ZIP>34108
<PHONE>9419231949
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1726 MEDICAL BOULEVARD, SUITE 201
<STREET2>SUITE 201
<CITY>NAPLES
<STATE>FL
<ZIP>34108
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>AMERICAN COMMUNICATIONS ENTERPRISES INC
<DATE-CHANGED>19990120
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g21480e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Date of Report (Date of earliest event reported)<BR>
<B>November&nbsp;30, 2009</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><U>NEOGENOMICS, INC.</U></B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><U><B>Nevada</B></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><B>333-72097</B></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><B>74-2897368</B></U></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><U> <B>12701 Commonwealth Drive, Suite&nbsp;9, Fort Myers, Florida</B></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><U><B>33913</B></U></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>(239)&nbsp;768-0600</B></U><BR>
(Registrant&#146;s telephone number, including area code)
</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>
</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>








<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.02.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Effective as of November&nbsp;30, 2009, George Cardoza, age 47, has been appointed to the position of
Chief Financial Officer of NeoGenomics, Inc. (the &#147;<U>Company</U>&#148;). From March&nbsp;2008 to December
2009, Mr.&nbsp;Cardoza served as the Chief Financial Officer of Protocol Global Solutions, Inc., a
privately held international marketing company. Mr.&nbsp;Cardoza also served as the Controller of
Protocol Global Solutions from March&nbsp;2006 to March&nbsp;2008. From April&nbsp;1991 to March&nbsp;2006, Mr.
Cardoza was employed by Quest Diagnostics Inc., a diagnostic testing, information and services
company, in a number of positions, including the position of Controller&#151;Central Region from 2001
to March&nbsp;2006.</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">NeoGenomics Laboratories, Inc. (&#147;<U>NeoGenomics Laboratories</U>&#148;), the Company&#146;s wholly-owned
subsidiary, and Mr.&nbsp;Cardoza are parties to an offer letter dated November&nbsp;3, 2009 (the &#147;<U>Offer
Letter</U>&#148;) with respect to Mr.&nbsp;Cardoza&#146;s employment as Chief Financial Officer. The Offer Letter
provides that Mr.&nbsp;Cardoza&#146;s start date would be on or before December&nbsp;1, 2009 and that his salary
would be $190,000 per year. Beginning with the fiscal year ending December&nbsp;31, 2010, Mr.&nbsp;Cardoza
is also eligible to receive an incentive bonus payment which will be targeted at 30% of his base
salary based on 100% achievement of goals as agreed upon between Mr.&nbsp;Cardoza and the CEO of
NeoGenomics Laboratories and approved by the Board of Directors for such fiscal year. Mr.&nbsp;Cardoza
is also entitled to participate in all medical and other benefits that NeoGenomics Laboratories has
established for its employees. Mr.&nbsp;Cardoza will also be eligible for up to four (4)&nbsp;weeks of paid
time off per year.</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">The Offer Letter also provides that Mr.&nbsp;Cardoza will be granted an option to purchase up to 150,000
shares of the Company&#146;s common stock at an exercise price equivalent to the closing price per share
at which such stock was quoted on the NASDAQ Bulletin Board on the date prior to Mr.&nbsp;Cardoza&#146;s
start date. The option has a five year term, subject to continued employment, and 37,500 shares of
such option will vest on the first, second, third and fourth year anniversary of employment.</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">If NeoGenomics Laboratories terminates Mr.&nbsp;Cardoza without &#147;Cause&#148; (as defined in the Offer Letter)
then the Company agreed to pay Mr.&nbsp;Cardoza&#146;s base salary and maintain his employee benefits for a
six (6)&nbsp;month period from the date of the termination notice.</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">The Company and Mr.&nbsp;Cardoza entered into a Confidentiality, Non-Solicitation and Non-Compete
Agreement in connection with the Offer Letter. NeoGenomics Laboratories and Mr.&nbsp;Cardoza also
entered into a Relocation Agreement in connection with the Offer Letter pursuant to which
NeoGenomics Laboratories agreed to reimburse Mr.&nbsp;Cardoza for up to $20,000 in the aggregate for
certain commuting, temporary housing and permanent relocation expenses. Mr.&nbsp;Cardoza further agreed
to return a portion of such reimbursed relocation expenses to NeoGenomics Laboratories in the event
he resigns from his employment within the time period specified in such agreement.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Effective as of November&nbsp;30, 2009, Steven C. Jones, age 46, has been appointed to the position of
Executive Vice President, Finance. Mr.&nbsp;Jones previously served in the position of Acting Principal
Financial Officer and also serves as the Company&#146;s Director of Investor Relations. Mr.&nbsp;Jones has
served as a director of the Company since October&nbsp;2003. He is a Managing Director in Medical
Venture Partners, LLC, a venture capital firm established in 2003 for the purpose of making
investments in the healthcare industry. Mr.&nbsp;Jones is also the co-founder and Chairman of the Aspen
Capital Group and has been President and Managing Director of Aspen Capital Advisors since January
2001. Prior to that Mr.&nbsp;Jones was a chief financial officer at various public and private
companies and was a Vice President in the Investment Banking Group at Merrill Lynch &#038; Co. Mr.
Jones received his B.S. degree in Computer Engineering from the University of Michigan in 1985 and
his MBA from the Wharton School of the University of Pennsylvania in 1991. He is also Chairman of
the Board of Quantum Health Systems, LLC and T3 Communications, Inc. and serves on the Board of
Directors of Disc Motion Technologies, Inc.</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">During 2008, Mr.&nbsp;Jones earned $176,000 for various consulting work performed in connection with his
duties as Acting Principal Financial Officer. During the nine months ended September&nbsp;30, 2009, Mr.
Jones earned approximately $149,000 for various consulting work performed in connection with his
duties as Acting Principal Financial Officer.</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">A copy of the press release announcing the appointments of Mr.&nbsp;Cardoza and Mr.&nbsp;Jones is attached
hereto as Exhibit&nbsp;99.1.</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="7%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press Release of NeoGenomics, Inc. dated December&nbsp;3, 2009</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>NEOGENOMICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Jerome J. Dvonch
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Jerome J. Dvonch&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Principal Accounting Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: December&nbsp;4, 2009
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Exhibit&nbsp;Index</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Press Release of NeoGenomics, Inc. dated December&nbsp;3, 2009</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g21480exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g21480neologo.gif" alt="(Neogenomics Logo)">
</DIV>


<DIV align="center" style="font-size: 16pt; margin-top: 18pt"><B>NEOGENOMICS, INC<BR>
PRESS RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 16pt; margin-top: 18pt"><B>NeoGenomics Announces Executive Appointments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Ft. Myers, Florida &#151; December&nbsp;3, 2009 &#151; </B>NeoGenomics, Inc. (NASD OTC BB: NGNM<B>) </B>announced
today that Steven C. Jones has been appointed Executive Vice President, Finance and that George A.
Cardoza has joined the company as Chief Financial Officer. Mr.&nbsp;Cardoza will be responsible for
managing all internal financial affairs of the Company. In his new role, Mr.&nbsp;Jones will focus on
developing strategic initiatives on behalf of NeoGenomics as well as continue to serve as the
Company&#146;s Director of Investor Relations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Cardoza most recently served as Chief Financial Officer of Protocol Global Solutions,
Inc., a privately held international marketing company. Prior to joining Protocol Global Solutions
in 2006, Mr.&nbsp;Cardoza was employed by Quest Diagnostics in a variety of financial roles of
increasing responsibility.. While at Quest Diagnostics, George served as Controller of the Central
Region with responsibility for 11 major laboratories.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Douglas VanOort, Chairman and Chief Executive Officer, stated, &#147;I am delighted to welcome
George Cardoza to NeoGenomics. I had the privilege of working with George for eight years during
my own time at Quest Diagnostics and he brings outstanding financial management skills to our
company. We are also very pleased to have Steve Jones lead strategic initiatives for our company
in addition to his role in Investor Relations. Steve has served as &#147;Acting CFO&#148; for the last seven
years, and brings wealth of experience and strategic skills to his new role. We are deeply indebted
to him for his dedication and many contributions to the growth and success of NeoGenomics.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About NeoGenomics, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NeoGenomics, Inc. is a high-complexity CLIA&#151;certified clinical laboratory that specializes in
cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The
company&#146;s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow
cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in
Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the
needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For
additional information about NeoGenomics, visit http://www.neogenomics.org.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you
can find a fact sheet on the company, investor presentations, and more. Interested parties can
also access additional investor relations material, including an investment profile and an equity
research report, from Hawk Associates at http://www.hawkassociates.com or from the American
Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>For further information, please contact:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="55%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>NeoGenomics, Inc.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>The Investor Relations Group</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Steven C. Jones
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>Investor Relations:</I></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Director of Investor Relations
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Crawford</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(239) 325-2001
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(212) 825-3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">sjones@neogenomics.org
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">mcrawford@investorrelationsgroup.com</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">or</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Hawk Associates, Inc.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>Media Relations:</I></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Ms. Julie Marshall
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Janet Vasquez</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(305)-451-1888
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>(</B>212) 825-3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">neogenomics@hawkassociates.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">jvasquez@investorrelationsgroup.com</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;2&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g21480neologo.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21480neologo.gif
M1TE&.#EA:@"$`/<``````(````"``("`````@(``@`"`@,'!PL#<P*;*\`!,
MGP!0GP!2HP!2I054HPE8HQ!<I1->JA9>IAABJB-@F1]FJB=FKBEGLRIJIREK
MKBQQK#!LL#)RKS)PLSENGSQMMSAUKSISM#ESO3MZLD-LD$5SG$-WJ$%ZM42`
MM$.`NE!\IDEYMTI[NTF#MTV%NTJ$QE1WF%5XE5)^NU&&MU*$QE.*N%2,P5MU
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MVYNSQ:2YS)RUUYR]UZ.@GJ:EI::IJZ6HLZ.OUZ6MUJ2\UZ3`VZ;#VJVMKJNT
MWK"QLZFWUZR\V:Z\W*S'W*[+Y+6UK;6UMK>XN[BZO+6^W;;`QK7'U+7&WK7.
MXKV[M[J[O+V]QKO!W\/$Q;[&UKW&SKS%WKW&Y[W/XK[5Y,;`O\3+Y<;7Y\+8
M[,?'R,W-SM#1T\G-Y<O7X,[6Y\S>Z<[?[=/2T=;5UMC:V]7<ZM?@[=GG\-O:
MU=K;V=W>WMW@Y][D[MSEZMSH\>#K\./N].7BX.7DX.?GY^3I\.CK].GR]>WK
MY^_G]^OMZN[P[_#U]_3T\??W]_CZ_/G\^?S[^_[^_O_[\)^?H7Y_@?\```#_
M`/__````__\`_P#______R'Y!```````+`````!J`(0`AP```(````"``("`
M````@(``@`"`@,'!PL#<P*;*\`!,GP!0GP!2HP!2I054HPE8HQ!<I1->JA9>
MIAABJB-@F1]FJB=FKBEGLRIJIREKKBQQK#!LL#)RKS)PLSENGSQMMSAUKSIS
MM#ESO3MZLD-LD$5SG$-WJ$%ZM42`M$.`NE!\IDEYMTI[NTF#MTV%NTJ$QE1W
MF%5XE5)^NU&&MU*$QE.*N%2,P5MUC5YYD%Q[O5I[QEN&K%F%OEB,O5V2OV=V
M@F1\OV-[O6>#FV..L&*+PF.2NF.5PF.4QFUW@FIZBFV!M&E_PF^$F6J"P&V+
MIFJ-KFN,QFN8OVJ8Q&^AS'%Z@F^#E'.$G'.#KG&%MW"&P'&)OW&'PW:6MG.3
MR7&>QG.=RW6BQWM\?GI]@GN$>WN"AWJ&E'J&I'N)CGN,E'F.PWV3QWZ=NWZ;
MQ'R8S7NERWNMUH1[>X*#A86&BH2$E(2,A(B)BX6+E(6.G868NH2:RX2<SH&F
MR(2KSH2MSHF&A(N,C8V0DXZ<I8BAMHR>RXR<UHNLQ8NOSXVQU)2,C).4E):7
MF92<G):=M)"=QY.CS92DTY2EWI:HO9:HSIBQU)*UTI:YU92]WIF7E9R4E)N;
MG)N>I)ZFK9NENIJGUYRJT)RLU9RJVYNSQ:2YS)RUUYR]UZ.@GJ:EI::IJZ6H
MLZ.OUZ6MUJ2\UZ3`VZ;#VJVMKJNTWK"QLZFWUZR\V:Z\W*S'W*[+Y+6UK;6U
MMK>XN[BZO+6^W;;`QK7'U+7&WK7.XKV[M[J[O+V]QKO!W\/$Q;[&UKW&SKS%
MWKW&Y[W/XK[5Y,;`O\3+Y<;7Y\+8[,?'R,W-SM#1T\G-Y<O7X,[6Y\S>Z<[?
M[=/2T=;5UMC:V]7<ZM?@[=GG\-O:U=K;V=W>WMW@Y][D[MSEZMSH\>#K\./N
M].7BX.7DX.?GY^3I\.CK].GR]>WKY^_G]^OMZN[P[_#U]_3T\??W]_CZ_/G\
M^?S[^_[^_O_[\)^?H7Y_@?\```#_`/__````__\`_P#______PC^`.L)'$BP
MH,&#"!,J7,BPH<.'$"-*?(@NWL2+&#-F!*--H\>/(`LRR]`QI,F3$GMD4(>R
MI<N$K!;T>$FS)K4)"EK5W(ER'`<%'-[Q'/I1'`@%"U8178J1VD\&*80RG?JP
M504%#!XDH\IUH3LO#A8L4,"GJ]F#M#I@9;#@B\6S<)GY<+#V05FX/./I/4C-
M"X2U##+TPLOSW+-SV)ZY&\C,R%\&D!GX&$>X9KQKP'"=P^SL&JT:#P`KR*"T
M\LMXW@[\`C8LWKI<7#`P$/W`"V73+@UG!G8-WC1#&2(+;[$5=TMWF'$!>]8N
MG%_`D2NL.6<<)>H#N7(=,.?NT%7AD#/^1,%UX,"UQ=4_ZL[%VQVM$.!G.]BP
M*IZY`[C(>WN;?B)R8-DQ1TT/LPFG@`0NY+"$%I)H`\\U^.$RS'[]071==@>4
M@PX?.($'@1'4U/.-(TT`L44LZ+CS##"W+$==A0R=XTQV[2%S`G19]8",1?',
MXTXO:I281B_NR)B+<M"@!Z-!*@*8BS/GH./&8Y!A%4$%/?10@PM<]N!#""N4
M"$0>T]@7H7G\+7D=+MIYXXXQ*\1W`BWB:%/-G7@R,TH;;0R2QQ9--/&(-LB=
M22&,1K)GC3O3#+(!>`JXX(N=>%:CS3;,3-*&&EUT,<HH/.0`1!8H-ID=E/V9
M"@R4Z*22Q0?^X(W0@@]9UIJE"R%TD,$&&[10@Y<]>*$&$"82*2.`RRE)6#S8
M8-?FFUL`(<,#T9&2$#JS//)()[&`8U`\Q@2Y1![,O),:>^T1=LXP1[;7*+%;
M6%"E`BT8PL>]^/)AB!L\L."O#%[D*W`1)P`1J"/9Q,,-?MI=D^94Z*RHW&&M
MEMA$*JM0*]DA]@K,AQLSK.!O#QZ7?`@>5U@\2HHKYG++`2].%0\T^0W#G3%I
M$#O(-/6`P8`#8,R#T#N]=`)*)\9(M=`U?Y!AQK`FZE*D,^8I2U0\[LB#CC?O
MO!NU4/.,P``$,]1@]MEFSQ`"KQN`T(*6:,?=PQ"!Q($//IF@HTO^SF,RX\X[
MJ'DC\P&*O9-*$SDT\0DZ`[U3`02^,"/YY)*OTFD7>2!3#>6<,].,+X(D(8;=
M<@A>3\4&Q^+.,+A<,S@NSTP3*+E"-U[!!,R(L\WNNX_#C)]](J,[[\1O(\XX
MWKCB1QQVQP%-0=3D`<0CYP##V^#+9=-$%N%\*_8)</_:PPD=Z'J""[7*W8,-
M)C#1O-U_/&^0+$!XTLX!US,5#_[69).%%HPSB`\4X(.":.,3VS+&PP@B#VR<
M0@[X8-[=,F$Z@\0"")*X'S"Z@;W^;0&`!R'%V/A`"DI4XA`\D($,>,`'2KCP
MA28D!2]N\8<(VBT,?SC``@=RP0SBCX/^^N-?-CX8P(*,HP*0<8$;>A""$X`/
M#&#P@A2E",49D(`*=Y.@'&YA-0MB4(-`7,K^@.%!$![$9PQH@39T\0FD(<0=
MOT@$\R08!U=44"$]!&,'AVA&@Z`C.`RH0`@&60,?T,H'1C`"%S91PSG>[1ZN
M<T@>?[A'(B:$%AI[`!%Z08M.UJ(6E!#"#\)@PPD^8X<)F>0&*]G'@QC"`9#A
M`#,&LK]+S-%N^$B$,U")QR]2,HADY&,1#P(.&43&+N@8!B"R>,,<=E&2OEPE
M,,LX3(,LXQ%$@,`"'E""9982A[EXYD-ZZ(Y?BE&(ED3(/'3QB%3T8@=5>!_I
M8!$SC)#3G%?^0V<K#<).3^!"CG/T`QDV4<^,W%.:YPQF.A&RC$;<873,$X,8
M;D`!%(3H(P<-8SX5NL^"0$,.CL3'/9Z`E0-1HG8&Q6`Y$;I1:B;D'`!E7B*L
M40]Y@`4R,KF-/56*SZ&,T:4'<8<B;!@'',R`A-10!R4F4*4,T"*EDEBI1GVJ
MSVH.Y!8V_`,C\D`$,$C!!>!32UW<H+2(9)255JW'.4"*CR2H@`=0&(0N+/*.
M:M#"$"X0S@DN:E:>LI2J'$WK`2)H"FE00@HAL(`%6N`&4B!C'$(C!1)G(P%K
M]36J/<T+_JXAS(.X@@IED,9`T/&)-A"!!85TP0IZ`(86@$<*+!G^IU^GJEG>
M=-8@I;!#$5HP*S>T0A;;2D4LLO&.;?B"$DOL0&04`(+B-.2LP.3L0FF9B&?4
M@QS,((4;C-"#$6P@!"R`PBIB*Y!X&$*;D($`):")V;_65KH=C<<E=K&-AXTC
M&6X@GP5"P%I*^"(<\4"&V")C!)VF<K;8@V]:38&#%J`/#/[5AE32\8I'F)8'
MW'5P%&HPEBIQP+D(@6Y"%7P08,1A&-1H!1^D,`/>!LL0E,A#'CJ1BFB\HZZT
MX$,43J"Q`U6BE^VE[4[&2&*#>",.B5"6.JC1"TIXP0<GX,!W6=`%9)2U%X"$
MC!?*2A`1;[3(!:''/<*0B6R08X?O$`?^+8A`O@R$8`9&:"PS:)%E>AF8APB.
M[FT-<@V[)<$$+H@S*9(QCK+&0QC:DO$H^&`$WG*`+54*0?<*XF7`@MD@I[@;
M('B18R.X8`0HZ*\OQ*&.9:3BU`JLQSS4H8U>W,C#Y*!TGD>\9X.<8YEQR,0Z
M&D>-'$MA?&];@0R(H(9/I(,@[ZC!6NA5UDJ_M]9\AB`^["`($A*:(/'8!BV<
M?`+%AD`*AJ!%N=1A!.'<12#.'O)FH6V09^`2"3`H0@U0\#8P#%JG[XA%'J`@
M`R^!-4NA@8P$2E*/=%MFW=-%B#.:]P=7G$,==EUQ#1S,6E+00EN@T,4[YG%?
M4O!A!@O0,I[^@YQ@=A_D&8W$AR*>0=S&54/%OT8!!SIP`BDDHR(#X0.U5H+N
M67_9Y`<Y1R;"8#<QQ`!\X/XO2M]!C2ZP(%<H0)\7*)$,'V2E.`:G"9&!'E17
ME/(,H:B$%R;>VU50XQWIT$4J.M&+7C.Z!RV(P`)^7'"?6YKK"#G`^V8J$'ED
MHQ5N\(&+51C78S<.#&3I.<FCJXV$-^0:B8C@W311"%(P(]8"(0<R*M&##5A@
M!$;@0RL2Y@8%&$+Q*[VCI1O?T8:XPQ2EO($*QN<"'^RA%=6X<2H>H89[P1T%
M$UB`90^J^O>R/JT-B0<NWO>'84`\QX(_GPMD``59R*,>\>B!`A[^,,NZM[?X
MZN;-\3."<J*Z0LG9E8&N1N`#*4"``4%!/?[`?W#Q.SXB0H<H/LZP@SBSXNSU
M,`V=\`B]P`=8L0![,'*IEV#CIQ'O``O,1`5.L&)@-0,]0'V'<`*0,0$$1WP,
M>'\347[,\P>_X`[JX#NDP`,5`$NS<6[>MX",!X(3X0U#)T%V,`134`G,T`81
M$!D@T&Q^17]:MUD-"!+NX'4VE`1.T`/OAU,2T'T*.'\?V'H:X0R-)`=5,&#I
M]52R]GU3B'P:<0ZF4`4>(!;'5!I="(,C5H0F\0Y[(`$>P@8A%H1?>!+Q0`J/
M!AX4D`2:4%#R!PQ">!I$^#]@*!'Q0`O^(Q!RR_4`)$`&?I!+Q>>!070+G-4$
M2[`X'C$/M'`"'28<*+`*G&`'$@0(]10-P^((Y90+@>@2\0`,,),.@T`L6M`+
M7/80AY@"!1(9VV0;O?`(@W`'$J0(BY$-)&(PNJ!6!["*+7$96.,FO<`W.Q,1
M\=`*&@@88_$`&L`!+7`"&="-((`#$H0*L1`MTZ,-Y[`?6$,5U[$<ZU`QB>,)
MWL(0\T"-N1@9$-`#S*`7R.`GF;,-X6`*<F`&2D`L:H`,[M`-^`$S7!$/SX`N
M[9$-L6@BLE"+!$$+*%"/LZ$`#F`$OD`-U(`,><`GHT`.@&,,6-`$4)`%LX`.
MYL`NY($-O+3^$_)P+`"R'>Z`#&H@*IFS0,S0`W1A(`YP`K1B!#Y0`R"P`1?@
M9F;#`EN0!4L`!%=@!]>P(BUR'GB!&L-@/<O1#M@2+8*2#:,U)3@R`40`8N]@
M#-KR"+/@#A!)+$#@",00>?=@/8>!&Y?A+.VA#8^`.">2#K3P%,N%%2U`":M@
M<;[`"FW0*<4F#LR0!Y98D.Y@#K"G"!,2DV9A*FT2#\S`!B42`AH3&1S@!H=P
M"'P@149P`FNS`6[F1%#PE%NPDKKA"KDF3J:Q'JMR#N8%A\+Q`$90+C<F-.G0
MB]K2";K`#))@,9\`#O]!'@<@!YFP).7E#5F9"\H@"AJ@BPYP`1O^L"5.A`(H
M<`*JN0$=$`(R8`C#T@0[<R&KHB+X8`K024O7X`R<H)LAUP$RT`1;L`J%EF:E
MM2EYP`I[("I`H`9)8P[.D!_)J%:`$`:W\)X$$0Y9!@%[H`XX:3"-@`R]L`=0
M``5=(`G,X`F`D@6KD`ZJXC#UX`VXA@T.FG-5@@&1X`R+X@ZKD`7$`IY-=`)A
M8C"2``YW.3'H,0S2=@^6:1SJ(!L*4`/2T)#DT0WQ``Y[B9]YP'M/22;VP3JX
M@"IJ!7MSI(S&D0RA40-"P2P,,PRXV9@&(R2TV`Y*>@`PB7T'\`=$9S?`L*(#
M(4(<@'D"L9S)\@ZZT)2QD`Z7L1N*(1#^UY`)S(0/L#"DU<$'#&!9!1$QN^$P
MX/`-:Y(+=:E6LEE*^'`+BEH=8/``DV80\A`.,_(R[@`/!RHAIG,.MQ`'<=H\
M!T"G!3$E>'H0UT&)WT`>)GH.N`"G1)5+D22K=0H!XL`0*N(-AB$4K.JKCA0'
M7"2L!5$-$X`,#O$6X2";I!12]\"ET#D/*."""Y$\KGI+=[-RG?J>M,`"0RJN
MKXI+Y@JM"B$//@!BMI:IY(HWIP2O#$$-A;!#[G`+=0!1-Q0'IF"B^MH0S!"J
MY?6FAXI#L,"M!TM+!%&HS$1*B:"0$7L11_@^1&<*^9JQ%P%Y<1H&<F!'((L1
M\9`+S1-!)GM>LA<1#UZ'2_>@HBZ+$3&+#SETKC7;;I)'03N+$>[@3:Y`D3_K
M$%B%#[B`4D6+?W:#"TN+$;<0!JYP?4\K$>[P!XJ@LU4[$$<&L5M+$,_@"E\[
/@UX[MN5EMFB;M@X1$``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
